Ruggero Ridolfi

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Jeffrey S. Weber, John A. Thompson, Omid Hamid et al. · Clinical Cancer Research · 2009 · 563 citations · Full text

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Anna Maria Di Giacomo, Paolo A. Ascierto, Lorenzo Pilla et al. · The Lancet Oncology · 2012 · 280 citations

Oncology, Single-arm Phase 2, Melanoma +6

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni et al. · Journal of Translational Medicine · 2014 · 162 citations · Full text

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Michele Maio, Riccardo Danielli, Vanna Chiarion‐Sileni et al. · Annals of Oncology · 2013 · 140 citations

Skin Cancer, Ophthalmology, Medicine +6

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo et al. · Annals of Oncology · 2014 · 139 citations · Full text

Oncology, Italian Network, Medicine +9